Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients
about
Review of vancomycin-induced renal toxicity: an updateOptimizing the Clinical Use of VancomycinRisk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort studyVancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii.Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients: developing and testing of a dosing nomogramVancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens.Therapeutic drug monitoring of antimicrobials.Optimization of time to initial vancomycin target trough improves clinical outcomesNew Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients.Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?Management of antibiotic resistance in the intensive care unit setting.Vancomycin dosing in patients on intermittent hemodialysis.Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients.Vancomycin dosing and monitoring 2 years after the guidelines.Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis.Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections.The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.How to use vancomycin optimally in neonates: remaining questions.Vancomycin dosing nomograms targeting high serum trough levels in different populations: pros and cons.Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients.Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients.A specially tailored vancomycin continuous infusion regimen for renally impaired critically ill patients.In vivo activity of vancomycin combined with colistin against multidrug-resistant strains of Acinetobacter baumannii in a Galleria mellonella model.Application of Intrawound Vancomycin Powder during Spine Surgery in a Patient with Dialysis-Dependent Renal Failure.Colistin and anti-Gram-positive bacterial agents against Acinetobacter baumannii.Failure of vancomycin continuous infusion against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.Influence of Mechanical Ventilation on the Pharmacokinetics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients.Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model.Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice.Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults.A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals.Design and prospective validation of a dosing instrument for continuous infusion of vancomycin: a within-population approach.
P2860
Q26746932-622A202E-F79F-4A48-BD96-737D52B5E947Q28069334-2B4FB140-B2C7-485F-ABF7-7BB7E95B46E6Q33751736-2CB9E4E3-C68D-403A-95B1-C17B416A6290Q34026240-224025B0-C6B5-4BD0-87E9-04C13F180FC8Q34274190-037926C0-644D-49AC-9954-001B314BA52FQ34309445-581B0FEA-5D56-4E72-8BCB-C2B4999BA166Q34777837-8FC5E94C-F7B0-4567-8B77-364E4A57285EQ35004943-A822EB60-E970-4F22-BF70-CA5AA9BFA74DQ35640430-0F2F9774-247A-40DB-BFFF-A710B3FDAA92Q35862844-C7FF64B8-FB2F-4F00-A825-F5496796B69CQ37120168-570BFD99-39FC-4DBE-85FF-F9931D234602Q37516599-0B476D1F-CEBA-4050-8A79-B8AF3FA3C10EQ37700552-15F3BD2D-E855-40B3-8C2F-FBD4A3D9F430Q37845424-9F961D73-EBBC-4FD1-AADC-BFFEEC0A7D6CQ37867260-EF9FF9F1-DC03-4001-B47A-3CF9A3498A2DQ37892556-B4F99468-706F-45FB-848A-F2795442A868Q38000242-821F3CF6-0F42-4958-AFB8-0E3722DE438FQ38258649-9580E0E8-A70E-42B1-B6B7-05C2DACFF66FQ38417173-D41A485C-C02E-46D0-BA9D-1B34BBB3B29EQ38569678-FEB36812-E365-447E-90A2-5771AD23638AQ38818376-EE20A4C8-5CC7-484F-9AAF-038B38155478Q39048274-B10078D1-B291-41C6-A317-4DF63C4270BDQ39386583-A69E5B73-6E55-4613-A299-EEDE3C681864Q40104555-1DE63DF0-7976-46DB-B0FC-07AEA437AAE3Q40936660-6264BE01-B4D4-49C5-9A4C-975D657755EFQ41103109-12C35F18-F326-416F-8EC0-D8A87E0F424BQ41736250-6A305FC8-96EA-4FE5-BF79-EFDC52FF425EQ42147280-8E8E78F2-177B-4D76-8640-2160CA9CD995Q42689710-AE765E6A-C700-4FA5-8231-545CBE36E930Q42772417-258A74E8-36BC-4C05-AA1F-C1ABFDDA80E1Q48089081-2DF15CE4-6047-452A-953F-52CC99F2D604Q48197188-4AF508AD-874A-4D31-9B35-AA816D6211F0Q49142591-9C29AE9A-2EAE-4434-A0C9-365D5C0252ACQ51047130-D1F04EBD-6F9F-41BF-B45A-66C23ADCABF0
P2860
Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prospectively validated dosing ...... ion in critically ill patients
@en
Prospectively validated dosing ...... on in critically ill patients.
@nl
type
label
Prospectively validated dosing ...... ion in critically ill patients
@en
Prospectively validated dosing ...... on in critically ill patients.
@nl
prefLabel
Prospectively validated dosing ...... ion in critically ill patients
@en
Prospectively validated dosing ...... on in critically ill patients.
@nl
P2093
P2860
P356
P1476
Prospectively validated dosing ...... ion in critically ill patients
@en
P2093
Camilla Negri
Federica Pavan
Francesco Cristini
Mario Furlanut
Massimo Crapis
Pierluigi Viale
P2860
P304
P356
10.1128/AAC.01149-08
P407
P50
P577
2009-02-17T00:00:00Z